Pharma companies could develop multiple small molecule drugs for related indications, rather than focus on a single molecule, to allow for staggered launch dates that would protect some uses from Medicare price negotiation beginning nine years after approval, Eli Lilly and Company CEO David Ricks suggested during a JP Morgan webinar on the impact of the Inflation Reduction Act 14 June.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?